Analysts See Over 30% Revenue Growth for Harmony Biosciences in Q4 2025 Preview
Harmony Biosciences will publish Q4 2025 earnings later this month with analysts forecasting revenue growth exceeding 30% year over year, driven by increased Xywav market penetration, and adjusted EPS near breakeven. Investors will monitor management’s updated 2026 guidance and operating margin outlook in the upcoming release.
1. Preview Highlights Analyst Estimates
Analysts anticipate Harmony Biosciences to report Q4 2025 revenue exceeding 30% year-over-year growth, largely attributed to robust sales of its sleep-disorder therapy Xywav. Consensus adjusted EPS estimates hover around breakeven, reflecting continued investment in commercial expansion.
2. Xywav Sales as Primary Growth Driver
Xywav’s expanding market penetration in the narcolepsy and idiopathic hypersomnia segments is the key catalyst behind revenue projections. Strengthening physician adoption and ongoing patient enrollment trends are expected to support top-line momentum.
3. Focus on 2026 Guidance and Margin Outlook
Investors will scrutinize any revisions to full-year 2026 revenue guidance as well as management’s commentary on operating margins. Improvements in cost structure and scale benefits from growing Xywav sales will be critical for profitability targets.